Clinical Trials Directory

Trials / Completed

CompletedNCT04937803

Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)

Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS): A Prospective, Multi-Center, Randomized-Controlled Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
216 (actual)
Sponsor
Harbin Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The DCB-ACS trial is a prospective, multi-center, non-inferiority, randomized controlled trail. The purpose of this trial is to evaluate the safety and efficacy of drug-coated balloon(DCB) in de novo lesions for acute coronary syndromes (ACS) .

Detailed description

Patients with ACS and indications for percutaneous coronary intervention were randomly assigned (1:1) to receive angioplasty with DCB or implantation of a Zotarolimus-Eluting Coronary Stent(ZES) . Dual anti-platelet therapy was given according to current guidelines. Follow-up was originally scheduled at by telephone or clinical visit at 1 month, 6 months, 12 months, and 24 months after discharge, and coronary angiography and FFR measurements will be carried out at 9 months.The primary objective is to show non-inferiority of DCB versus drug-eluting stent(DES) regarding the functional assessment of target lesion by FFR at 9 months.

Conditions

Interventions

TypeNameDescription
DEVICEDrug-coated balloonDrug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
DEVICEZotarolimus-Eluting Coronary StentZotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .

Timeline

Start date
2021-04-19
Primary completion
2023-02-18
Completion
2023-11-17
First posted
2021-06-24
Last updated
2024-07-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04937803. Inclusion in this directory is not an endorsement.